Seek Returns

ILMN vs. SNY: Illumina vs. Sanofi Stock Comparison

How do Illumina (ILMN) and Sanofi (SNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Illumina (ILMN) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ILMN is classified in Life Sciences Tools & Services while SNY is classified in Pharmaceuticals.

Illumina (ILMN) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Illumina (ILMN) and Sanofi (SNY)
Profile ItemILMNSNY
NameIllumina Inc.Sanofi ADR
Country/RegionUnited StatesFrance
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization32.23 billion USD112.71 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJuly 28, 2000July 1, 2002
Security TypeCommon StockADR

Price Performance

Cumulative Growth

ILMN
SNY
GSPC
Loading price history…
Illumina (ILMN) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Illumina (ILMN) and Sanofi (SNY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Illumina (ILMN) and Sanofi (SNY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Illumina (ILMN) and Sanofi (SNY)
MetricILMNSNY
Total Return (1Y)79.70%2.73%
Total Return (3Y, Annualized)28.16%6.89%
Total Return (5Y, Annualized)-10.65%3.16%

Risk Profile

Drawdown History

ILMN
SNY
GSPC
Loading price history…
Illumina (ILMN) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Illumina (ILMN) and Sanofi (SNY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Illumina (ILMN) has an aggressive beta of 1.46, indicating higher sensitivity to broad-market moves, while Sanofi (SNY) is defensive at 0.28 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk profile metrics for Illumina (ILMN) and Sanofi (SNY)
MetricILMNSNY
Volatility (1Y, Annualized)48.47%23.60%
Beta (5Y)1.460.28
Max Drawdown (5Y)-82.95%-33.52%
Avg. Volume (3M)2.77M3.29M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ILMN and SNY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Illumina (ILMN) and Sanofi (SNY)
MetricILMNSNY
Sharpe Ratio (1Y)1.56-0.07
Sortino Ratio (1Y)2.25-0.10

Profitability

ROE (TTM)

Illumina (ILMN) at 32.39% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for ILMN.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.39%

Max
109.18%
ILMN
32.39%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.72%

Max
109.18%
Q3
6.23%
SNY
5.72%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Illumina (ILMN) vs. Sanofi (SNY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Illumina (ILMN) at 19.72% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.72%

ILMN
19.72%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.20%

Max
18.05%
SNY
8.20%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Illumina (ILMN) vs. Sanofi (SNY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Illumina (ILMN) at 20.02% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max
83.12%
ILMN
20.02%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.89%

Max
83.12%
SNY
30.89%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Illumina (ILMN) vs. Sanofi (SNY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Illumina (ILMN) and Sanofi (SNY)
MetricILMNSNY
ROE (TTM)32.39%5.72%
ROA (TTM)8.32%5.31%
Net Margin (TTM)19.72%8.20%
Operating Margin (TTM)20.02%30.89%
Gross Margin (TTM)67.68%73.68%

Growth

Revenue Growth

Sanofi (SNY) at 5.49% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Illumina (ILMN) vs. Sanofi (SNY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Sanofi (SNY) reports EPS growth of 39.43%, ranked against its industry; Illumina (ILMN) has no EPS growth figure this period.

Loading chart…
Illumina (ILMN) vs. Sanofi (SNY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Illumina (ILMN) and Sanofi (SNY)
MetricILMNSNY
Revenue Growth (YoY)-0.66%5.49%
Revenue Growth (3Y CAGR)-1.78%4.82%
EPS Growth (YoY)--39.43%
EPS Growth (3Y CAGR)--6.02%

Financial Strength

Current Ratio (MRQ)

Illumina (ILMN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max
25.13
Q3
12.13
Median
5.52
ILMN
2.63
Q1
2.47
Min
0.10

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.12

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
SNY
1.12
Min
0.10
Loading chart…
Illumina (ILMN) vs. Sanofi (SNY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Sanofi (SNY) at 0.27 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.74

Max
1.42
ILMN
0.74
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.27

Max
1.42
Q3
0.65
SNY
0.27
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Illumina (ILMN) vs. Sanofi (SNY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Illumina (ILMN) and Sanofi (SNY)
MetricILMNSNY
Current Ratio (MRQ)2.631.12
Debt / Equity (MRQ)0.740.27
Net Debt / EBITDA0.850.96

Dividends

Dividend Yield (TTM)

Neither Illumina (ILMN) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Illumina (ILMN) vs. Sanofi (SNY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Illumina (ILMN) pays no dividend (payout 0.00%).

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

119.86%

SNY
119.86%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Illumina (ILMN) vs. Sanofi (SNY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Illumina (ILMN) and Sanofi (SNY)
MetricILMNSNY
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%119.86%

Valuation

P/E Ratio (TTM)

Both Illumina (ILMN) at 36.68 and Sanofi (SNY) at 23.40 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.68

Max
85.34
Q3
43.46
ILMN
36.68
Median
26.69
Q1
13.30
Min
0.07

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.40

Max
85.34
Q3
43.46
Median
26.69
SNY
23.40
Q1
13.30
Min
0.07
Loading chart…
Illumina (ILMN) vs. Sanofi (SNY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Illumina (ILMN) at 7.10 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.10

Max
58.18
Q3
25.77
Median
7.30
ILMN
7.10
Q1
3.01
Min
0.01

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.21

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
SNY
2.21
Min
0.01
Loading chart…
Illumina (ILMN) vs. Sanofi (SNY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Sanofi (SNY) at 1.38 looks cheap against book in the lower P/B ratio quartile, while Illumina (ILMN) at 10.30 carries a premium in the upper quartile — a clear price-to-book gap.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.30

Max
13.53
ILMN
10.30
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
SNY
1.38
Min
-5.59
Loading chart…
Illumina (ILMN) vs. Sanofi (SNY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Illumina (ILMN) and Sanofi (SNY)
MetricILMNSNY
P/E Ratio (TTM)36.6823.40
P/S Ratio (TTM)7.102.21
P/B Ratio (MRQ)10.301.38
Free Cash Flow Yield (TTM)2.67%7.17%